Introduction
============

Osteosarcoma (OS) is the most prevalent primary bone related malignancy, accounting for \~20% of primary malignancies of bone among children and adolescents ([@b1-etm-0-0-4360]). Receptor activator of nuclear factor κB (RANK) is key to the RANK/receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) cascade and regulates a range of physiological processes. Most notably, RANK signaling is essential for bone homeostasis due to its role in the differentiation and activation of bone-absorbing osteoclasts ([@b2-etm-0-0-4360]). Notably, a previous review has reported that deregulation of the RANK signaling pathway is involved in the progression of multiple human diseases ([@b3-etm-0-0-4360]). The development of molecular therapies aimed at inhibiting the RANK pathway has been prominent, and a better understanding of this pathway is crucial for future utilization of these evolving drugs. In cancer, the importance of RANK ([@b4-etm-0-0-4360]) has been highlighted in multiple studies ([@b5-etm-0-0-4360]--[@b8-etm-0-0-4360]) that demonstrate its role in the acceleration of cancer metastasis to the bone.

The RANK downstream signal transducer, Akt, also known as protein kinase B (PKB), is essential in the phosphatidylinositol 3-kinase (PI3K) pathway and is important in the maintenance of numerous cellular processes, including cell proliferation, differentiation and metabolism ([@b9-etm-0-0-4360]). Three distinct genes encode for Akt1 (PKBa), Akt2 (PKBb) and Akt3 (PKBc), and for proteins sharing up to 80% amino acid sequence identity in mammalian cells ([@b10-etm-0-0-4360]). Evidence indicates that Akt1 is crucial for the initiation and metastasis of various cancers by agonizing its downstream effectors glycogen synthase kinase-3a/b and mechanistic target of rapamycin, whereas Akt2 antagonizes this effect to inhibit cancer progression ([@b10-etm-0-0-4360]). However, in lung carcinoma studies a contradictory result is observed ([@b11-etm-0-0-4360]), which reveal that Akt1 inhibits tumor cell migration and metastasis by promoting relevant protein degradation while Akt2 does the opposite. In particular, constitutively active protein kinase A signaling due to the loss of the bone tumor suppressor gene resulted in considerable amounts of Akt, which is essential in signal transduction of physiological processes as well as in neoplasia formation in the PI3K/Akt pathway. In addition, part of the tumorigenic effect of RANK may be due to stimulation of the activation of Akt ([@b12-etm-0-0-4360],[@b13-etm-0-0-4360]). A feature of a variety of human cancers, including lung cancer ([@b6-etm-0-0-4360]), is uncontrolled activation of the Akt pathway.

Therefore, it is hypothesized that RANK participates in the initiation and metastasis of OS partially through the activation of Akt. In the present study, the expression of RANK and Akt1 in 78 OS and 15 osteochondroma patient samples was analyzed by immunohistochemistry in order to characterize the potential interplay between the RANK and Akt factors and their association with tumor progression and metastasis.

Materials and methods
=====================

### Patient and sample preparation

In total, 78 patients with primary OS were screened from the archives of the Department of Pathology of Xiangya Hospital of Central South University (Changsha, China). Two independent pathologists in this department reached a consensus to confirm each patient diagnosis. Next, a block of formalin-fixed, paraffin-embedded biopsy material without neoadjuvant chemotherapy and surgery was obtained for staining in the present study. Based on pathological classification, 31 osteoblastic, 18 fibroblastic, 15 chondroblastic, 12 teleangiectatic and 2 giant cell OS samples were selected. Surgery of all patients was undertaken at the Department of Orthopedics of Xiangya Hospital between 2008 and 2014 ([Table I](#tI-etm-0-0-4360){ref-type="table"}). In addition, Enneking staging ([@b14-etm-0-0-4360]) was utilized as the surgical classification for all cases. As a negative control, 15 (9M/6F) femoral or tibial osteochondroma samples from 2012 to 2014 were collected in the Department of Orthopedics of Xiangya Hospital (Changsha, China). These samples were from 9 males and 6 females, with a mean age of 22.4 (8--37 years). The Medical Review Board of the Central South University approved the study protocol. Furthermore, informed patient consent was obtained prior to the study.

### Immunohistochemistry

Consecutive 4-µm paraffin-embedded sections were stained with antibodies against RANK and Akt1 (ab13918, ab54752, 1:150; Abcam, Cambridge, MA, USA) in accordance with the manufacturer\'s instructions. In brief, target retrieval was performed by heating in citrate buffer (pH 6.0) at 99°C for 30 min. The samples were then incubated with the primary antibody overnight at 4°C. The following day, Goat anti-mouse secondary antibody (ZDR-5307, 1:100, ZSGB-BIO, Beijing, China) was added and the samples were incubated for 1 h at room temperature. Images were then captured using a detection system (Leica Microsystems GmbH, Wetzlar, Germany). A negative control was set, by omitting the primary antibody, in order to measure the non-specific conjugation of antibodies. In total, 15 osteochondromas served as the control group. Quantitative assessment was performed under high-power magnification (x400) by analyzing the protein expression in 500 adjacent tumor cells. The final score was calculated by combining a score allocated according to the percentage of positive tumor cells (0, none; 1, 1--29%; 2, 30--69% and 3, 70--100%) and a score for expression intensity (0, none; 1, weak; 2, moderate and 3, strong). The result was then divided into negative (−, 0), weakly positive (+, 1--4), median positive (++, 5--8) and strongly positive (+++, 9--12) on the basis of the final score value. Finally, the scores were accepted if the two investigators agreed with the values. Otherwise, the values were re-estimated until a consensus was reached. The conclusions were in complete agreement in 80% of the cases, which indicated that the scoring method was highly reproducible. Thus, all results were evaluated independently by two investigators in order to reach a consensus.

### Statistical analysis

All statistical analyses were performed using Statistical Product and Service Solutions version 21.0 software (IBM SPSS, Armonk, NY, USA). An association analysis of RANK and Akt1 with each other and with their respective clinicopathological parameters was performed using Pearson\'s χ^2^ test. In addition, survival analysis was conducted by the Kaplan-Meier method and Cox regression method was utilized in the multivariate analysis. A two-sided P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Immunohistological detection of RANK and Akt1

The expression of RANK and Akt1 was positive in 60 (76.9%) and 58 (74.4%) of OS patients, respectively. The specific results are shown in [Table I](#tI-etm-0-0-4360){ref-type="table"}. Of these cases, RANK expression was detected as weak in 28 (46.7%), moderate in 19 (31.7%) and strong in 13 (21.7%) cases, while Akt1 exhibited 30 (51.7%) weak, 19 (32.8%) moderate and 9 (15.5%) strong expression. Representative images of RANK and Akt1 staining in OS and osteochondroma tissues are shown in [Figs. 1](#f1-etm-0-0-4360){ref-type="fig"} and [2](#f2-etm-0-0-4360){ref-type="fig"}. In addition, correlation analysis demonstrated a strong positive association between RANK and Akt1 with a coefficient r=0.797 (P\<0.001) using the Spearman correlation method. The detailed expression results for RANK and Akt1 are shown in [Table II](#tII-etm-0-0-4360){ref-type="table"}.

### Clinicopathological correlation of RANK and Akt1 expression

Among the 78 cases of OS, 46 were male and 32 were female patients. In total, 50 patients received conventional chemotherapy following surgery. The patient follow-up duration ranged between 2 and 44 months (median, 17 months with a standard deviation of 10.8 months), determined from the day of the surgery. In the whole follow-up period, 31 patients (39.7%) developed lung metastases and 4 patients (5.1%) had restricted local recurrence. In addition, 28 patients (23.1%) succumbed to tumor progression while 11 patients (14.3%) succumbed to other causes ([Table I](#tI-etm-0-0-4360){ref-type="table"}). The expression patterns of RANK or Akt1 exhibited no statistically significant differences according to patient gender. Furthermore, the expression patterns of RANK or Akt1 demonstrated no statistically significant differences according to the age (\>21 or ≤21 years) of the patients.

Patients receiving chemotherapy who showed no signs of metastasis, local recurrence or mortality were classified as responders while the rest were classified as non-responders. A good response to chemotherapy was negatively correlated with the development of metastases (r=−0.683, P\<0.05) and also associated with RANK (P\<0.05) and Akt1 (P\<0.05) expression.

### Survival analysis for RANK and Akt1

The prognostic significance of RANK and Akt1 was examined in OS by reclassification of the cases into lower (comprising negative and weakly positive in previous analyses) and higher (comprising positive and strongly positive in previous analyses).

In total, 38 patients were recruited for the survival analysis. Kaplan-Meier analysis displayed a significantly differentiated expression pattern between lower (−, +) and higher (++, +++) expression and the survival rate was lower in patients with RANK-expressing tumors ([Fig. 3](#f3-etm-0-0-4360){ref-type="fig"}). In addition, Akt1-expressing cases demonstrated a similar pattern with regard to the survival plot; Akt1-positive patients exhibited a relatively lower mean survival rate than Akt1-negative cases ([Fig. 4](#f4-etm-0-0-4360){ref-type="fig"}).

In multivariate analysis, Enneking staging (relative risk \[RR\]=3.01), response to chemotherapy (RR=3.20) and RANK expression (RR=8.77) were confirmed as independent prognostic factors for osteosarcoma, as shown in [Table III](#tIII-etm-0-0-4360){ref-type="table"}.

Discussion
==========

There is evidence that the RANK/RANKL/OPG axis functions as a regulator of diverse carcinogenesis ([@b15-etm-0-0-4360]). The downstream molecular mechanisms, however, are not completely understood. Akt1 is a RANK downstream signaling molecule and promotes tumor progression ([@b16-etm-0-0-4360],[@b17-etm-0-0-4360]). The present study utilized immunohistochemical methods to investigate the clinicopathological relevance of RANK and Akt1 expression to OS progression and their correlations.

The results are partially consistent with those of previous studies concerning RANK signaling. Since RANK signaling differs between physiological conditions and tumorigenesis ([@b17-etm-0-0-4360]), the well-known cancer-promoting factor Akt1, which is known to be activated by RANK *in vitro*, was selected for investigation in the present study. Since cytological experiments have revealed that RANK activation upregulates Akt1 and thus promotes OS cell motility by interplaying with RANKL ([@b17-etm-0-0-4360]), it is likely that RANK expression may be linked to cancer metastasis. In addition, RANK promotes OS cell proliferation through Akt and extracellular signal-regulated kinase 1/2 ([@b17-etm-0-0-4360]).

The correlation analysis of the present study supports the hypothesis that RANK and Akt1 may work together to promote OS progression. However, in the present study, it is difficult to determine whether RANK and Akt1 contribute together in cancer proliferation or metastasis or independently due to the limited size of the cohort. For the univariate analysis, the present study failed to find statistical significance between RANK or Akt1 expression and gender, age and the histological type of patients. From consideration of these results and those of previous consistent studies ([@b18-etm-0-0-4360]), it is hypothesized that RANK or Akt1 may not be tightly involved in human OS initiation but may function in tumor progression. It seems possible that the activity of the entire RANK/RANKL/OPG axis is involved in tumor progression and may be useful for predicting survival and response to chemotherapy. In addition, *in vitro* analyses have indicated that, through the activation of RANK, RANKL modulates gene expression involved in a wide range of cell activities such as protein synthesis and DNA regulation to affect cellular fate ([@b5-etm-0-0-4360],[@b15-etm-0-0-4360]). However, RANK signaling did not significantly affect the proliferation of OS cell lines in an *in vitro* model ([@b15-etm-0-0-4360]). By contrast, OPG gene therapy has been shown to directly inhibit OS progression through the inhibition of RANKL ([@b7-etm-0-0-4360]).

The long-term survival rate in OS patients treated with conventional chemotherapy has been reported as 28% ([@b19-etm-0-0-4360]). Clinical parameters such as tumor size and histological response to chemotherapy appear to be of prognostic value ([@b20-etm-0-0-4360]). Therefore, future efforts should be placed on the prediction of non-responders to conventional chemotherapy. In these patients, combining neoadjuvant chemotherapy with targeted medicine, such as chromatin-modifying drugs ([@b21-etm-0-0-4360]) or RANKL-related antibodies ([@b10-etm-0-0-4360],[@b12-etm-0-0-4360]) may improve the survival rate. In conclusion, the present study demonstrates that RANK expression in OS is correlated with clinicopathological characteristics and it is an independent prognostic factor in OS progression.
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![RANK expression in human osteosarcomas and osteochondromas. Representative images are shown for samples that are (A) osteosarcoma negative, (B) osteosarcoma weakly positive, (C) osteosarcoma positive, (D) osteosarcoma strongly positive and (E) osteochondroma negative. Magnification 10×20 for the inset and 10×100 for the main image, which is a magnified image of the area defined by the black rectangle in the inset. RANK, receptor activator of nuclear factor κB.](etm-13-06-2862-g00){#f1-etm-0-0-4360}

![Akt1 expression in human osteosarcomas and osteochondromas. Representative images are shown for (A) osteosarcoma negative, (B) osteosarcoma weakly positive, (C) osteosarcoma positive, (D) osteosarcoma strongly positive and (E) osteochondroma negative. Magnification 10×20 for the inset and 10×100 for the main image, which is a magnified image of the area defined by the black rectangle in the inset.](etm-13-06-2862-g01){#f2-etm-0-0-4360}

![Survival analysis of RANK. RANK, receptor activator of nuclear factor κB. blue, 0.00: RANK- (negative), green, 1.00: RANK+ (weakly positive), yellow, 2.00: RANK++ (median positive) and purple, 3.00: RANK+++ (strongly positive). X axis, months; Y axis, survival rate (%).](etm-13-06-2862-g02){#f3-etm-0-0-4360}

![Survival analysis of Akt1. Blue, 0.00: Akt1- (negative), green, 1.00: Akt1+ (weakly positive), yellow, 2.00: Akt1++ (median positive) and purple 3.00: Akt1+++ (strongly positive). X axis, months; Y axis, survival rate (%).](etm-13-06-2862-g03){#f4-etm-0-0-4360}

###### 

Clinicopathological data of patients with osteosarcoma and positive RANK or Akt1 expression.

                      RANK positive   AKT1 positive                         
  ------------------- --------------- --------------- -------- ------------ --------
  Gender              78              60 (76.9)       \>0.05   58 (74.4)    \>0.05
    Male              46              36 (78.2)                33 (71.7)    
    Female            32              24 (70.5)                25 (78.1)    
  Age                                                 \>0.05                \>0.05
    \>21 years        42              33 (78.6)                30 (1.4)     
    ≤21 years         36              27 (75.0)                28 (77.8)    
  Histological type                                   \>0.05                \>0.05
    Osteoblastic      31              27 (87.1)                23 (74.2)    
    Chondroblastic    15              10 (66.6)                11 (73.3)    
    Telangiectatic    12                9 (75.0)                 8 (66.7)   
    Fibroblastic      18              13 (72.2)                14 (77.8)    
    Giant cell          2               1 (50.0)               2 (100.0)    
  Staging                                             0.05                  \<0.05
    Enneking 1&2A     37              24 (64.9)                23 (62.2)    
    Enneking 2B&3     41              36 (87.9)                35 (85.4)    
    Chemotherapy      50              41 (82.0)       \<0.05   39 (78.0)    \<0.05
    Responder         21              14 (66.7)                13 (61.9)    
    Non-responder     29              27 (93.1)                26 (89.7)    

RANK, receptor activator of nuclear factor κB.

###### 

Correlation of RANK and Akt1 expression (n).

             RANK -   RANK +   RANK ++   RANK +++
  ---------- -------- -------- --------- ----------
  AKT1 -     15         3        1       1
  AKT1 +       2      21         6       1
  AKT1 ++      1        4      10        4
  AKT1 +++     0        0        2       7

Coefficient of correlation, r=0.797, P\<0.001. RANK, receptor activator of nuclear factor κB.

###### 

Multivariate survival analysis of patients with osteosarcoma.

  Factor                  Relative risk   95% CI         P-value
  ----------------------- --------------- -------------- ---------
  Chemotherapy response   3.20            1.50--6.82     0.003
  Enneking staging        3.01            1.40--6.84     0.005
  RANK                    8.77            1.11--68.969   0.039

RANK, receptor activator of nuclear factor κB; CI, confidence interval.
